Scipher Medicine Increases Patient Access for PrismRA? by Expanding Intended Use in Autoimmune Patients

• Expanded intended use for the blood test validated in Network-004 study.
• Now, most rheumatoid arthritis patients can be tested at any point in their clinical journey.
• Test enables providers to identify optimal rheumatoid arthritis treatment for more than 600,000 patients annually.

For more information: https://www.sciphermedicine.com/scipher-medicine-introduces-precision-medicine-for-autoimmune-disorders/